Scarica l'app Stockscreener
27.79
1.02%
0.28
Precedente Chiudi:
$27.51
Aprire:
$26.12
Volume 24 ore:
3.99M
Relative Volume:
1.00
Capitalizzazione di mercato:
$1.52B
Reddito:
$14.34M
Utile/perdita netta:
$-199.00M
Rapporto P/E:
-7.0893
EPS:
-3.92
Flusso di cassa netto:
$-183.51M
1 W Prestazione:
-58.95%
1M Prestazione:
-52.02%
6M Prestazione:
+176.24%
1 anno Prestazione:
+274.02%
Intervallo 1D:
$25.62
$28.39
Intervallo di 1 settimana:
$22.85
$36.19
Portata 52W:
$5.50
$71.50
Uniqure N V Stock (QURE) Company Profile
Nome
Uniqure N V
Settore
Industria
Telefono
1-339-970-7000
Indirizzo
PAASHEUVELWEG 25A, AMSTERDAM
Confronta QURE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
27.79 | 1.69B | 14.34M | -199.00M | -183.51M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-04 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-08-14 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2025-04-01 | Ripresa | Chardan Capital Markets | Buy |
| 2024-12-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-02-29 | Downgrade | Goldman | Buy → Neutral |
| 2023-12-19 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-17 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-05-21 | Iniziato | UBS | Neutral |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-04-01 | Aggiornamento | Mizuho | Neutral → Buy |
| 2021-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-24 | Iniziato | H.C. Wainwright | Buy |
| 2020-11-11 | Iniziato | Berenberg | Buy |
| 2020-11-09 | Iniziato | Jefferies | Buy |
| 2020-11-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-08-25 | Iniziato | Raymond James | Strong Buy |
| 2020-07-31 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Downgrade | Mizuho | Buy → Neutral |
| 2020-06-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Iniziato | Cowen | Outperform |
| 2019-12-03 | Iniziato | Goldman | Buy |
| 2019-11-05 | Iniziato | Credit Suisse | Outperform |
| 2019-10-11 | Iniziato | Stifel | Buy |
| 2019-09-25 | Iniziato | Bernstein | Outperform |
| 2019-09-12 | Iniziato | Mizuho | Buy |
| 2019-07-30 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-07-08 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Iniziato | Piper Jaffray | Overweight |
| 2019-03-29 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Uniqure N V Borsa (QURE) Ultime notizie
NASDAQ: QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - NewMediaWire
What data driven models say about uniQure N.V.’s futureMarket Volume Report & Long Hold Capital Preservation Tips - newser.com
Predicting uniQure N.V. trend using moving averages2025 Technical Patterns & Entry and Exit Point Strategies - newser.com
uniQure NV Hits Day Low of $26.25 Amid Price Pressure - Markets Mojo
NASDAQ: QURE Investigation Reminder: Kessler Topaz Meltzer - GlobeNewswire
NASDAQ: QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - GlobeNewswire Inc.
Uniqure NV expected to post a loss of 90 cents a shareEarnings Preview - TradingView
Volatility clustering patterns for uniQure N.V.Entry Point & Short-Term Trading Opportunity Alerts - newser.com
Can uniQure N.V. (UQ1) stock sustain revenue momentumJuly 2025 Patterns & Fast Moving Trade Plans - newser.com
UniQure’s FDA Nightmare: How A Single Therapy Sparked A $300M Meltdown! - Smartkarma
Is uniQure N.V. stock trading at a premium valuation2025 Key Lessons & Daily Technical Forecast Reports - newser.com
uniQure to Announce Third Quarter 2025 Financial Results - The Manila Times
uniQure Stock Tumbled 55% Today: What’s The FDA Angle? - MSN
uniQure (NASDAQ: QURE) to Host Earnings Call Nov. 10 at 8:30 a.m. ET, before market open - Stock Titan
The FDA is a mess, but don’t blame it for everything - statnews.com
uniQure N.V. stock outlook for YEARMarket Performance Report & Expert Approved Momentum Trade Ideas - newser.com
What catalysts could drive uniQure N.V. stock higherPortfolio Risk Report & Intraday High Probability Alerts - newser.com
Risk adjusted return profile for uniQure N.V. analyzedJuly 2025 Action & High Accuracy Trade Signal Alerts - newser.com
Can uniQure N.V. stock hit record highs againJuly 2025 Institutional & Fast Entry and Exit Trade Plans - newser.com
How institutional buying supports uniQure N.V. stockMarket Activity Recap & Entry Point Confirmation Signals - newser.com
Can uniQure N.V. stock hit analyst price targets2025 Biggest Moves & Verified Entry Point Detection - newser.com
Has uniQure’s Volatile 63% Drop Created a Compelling Opportunity After Pipeline News? - simplywall.st
Biohaven Stock Hits 52-Week Low, Cuts R&D Spending After FDA Rejection - Benzinga
UNIQURE ALERT: Bragar Eagel & Squire, P.C. is Investigating uniQure N.V. on Behalf of ... - Bluefield Daily Telegraph
UNIQURE ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
uniQure (NASDAQ:QURE) Trading Down 14.7% Following Analyst Downgrade - MarketBeat
uniQure NV Hits Day Low of $22.85 Amid Price Pressure - Markets Mojo
Y Intercept Hong Kong Ltd Purchases New Stake in uniQure N.V. $QURE - MarketBeat
uniQure (QURE): Examining Valuation Following Recent Share Price Volatility - simplywall.st
RBC Capital Maintains uniQure N.V. (QURE) Outperform Recommendation - Nasdaq
Traders Purchase Large Volume of uniQure Call Options (NASDAQ:QURE) - MarketBeat
uniQure N.V. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential ... - Enidnews.com
uniQure N.V. INVESTIGATION: Kirby McInerney LLP Announces - GlobeNewswire
QURE ALERT: UniQure Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact The Firm - ACCESS Newswire
UniQure Is Latest Gene Therapy Sponsor Surprised By US FDA Reversal - Citeline News & Insights
Chardan Capital Has Lowered Expectations for uniQure (NASDAQ:QURE) Stock Price - MarketBeat
Top Small Cap Stocks To Follow TodayNovember 3rd - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating uniQure N.V. (QURE) And Encourages Stockholders to Connect - ACCESS Newswire
uniQure N.V. Securities Lawsuit Investigation - Claim Depot
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy - Benzinga
uniQure (QURE) Sees Analyst Price Target Lowered by RBC Capital - GuruFocus
uniQure (NASDAQ:QURE) Shares Gap DownHere's Why - MarketBeat
uniQure (QURE) Analyst Rating Update: Goldman Sachs Lowers Price Target | QURE Stock News - GuruFocus
uniQure (QURE) Shares Drop Over 15% Amid Market Shifts - GuruFocus
Goldman Sachs Maintains UniQure NV(QURE.US) With Hold Rating, Cuts Target Price to $38 - 富途牛牛
NASDAQ: QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - Business Wire
UniQure: Controversy Abounds As Stock Price Halves On FDA News (NASDAQ:QURE) - Seeking Alpha
H.C. Wainwright Maintains UniQure NV(QURE.US) With Buy Rating, Cuts Target Price to $70 - 富途牛牛
Chardan Cuts Price Target on uniQure to $53 From $76, Keeps Buy Rating - MarketScreener
RBC Cuts Price Target on uniQure to $45 From $65, Keeps Outperform, Speculative Risk - MarketScreener
William Blair Downgrades uniQure N.V to Market Perform From Outperform - MarketScreener
Uniqure N V Azioni (QURE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Uniqure N V Azioni (QURE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Kaye Jack | Director |
Nov 04 '25 |
Sale |
30.34 |
38,810 |
1,177,517 |
20,439 |
5.44%
0.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):